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Posttranslational modiﬁcations (PTM) have been shown to be essential for protein function and
signaling. Here we report the identiﬁcation of a novel modiﬁcation, protein transfer of histamine,
and provide evidence for its function in G protein signaling. Histamine, known as neurotransmitter
and mediator of the inﬂammatory response, was found incorporated into mastocytoma proteins.
Histaminylation was dependent on transglutaminase II. Mass spectrometry conﬁrmed histamine
modiﬁcation of the small and heterotrimeric G proteins Cdc42, Gao1 and Gaq. The modiﬁcation
was speciﬁc for glutamine residues in the catalytic core, and triggered their constitutive activation.
TGM2-mediated histaminylation is thus a novel PTM that functions in G protein signaling. Protein
amonoaminylations, thus including histaminylation, serotonylation, dopaminylation and norepi-
nephrinylation, hence emerge as a novel class of regulatory PTMs.
Structured summary of protein interactions:
TGM2 enzymaticly reacts CDC42 by enzymatic study (View interaction)
TGM2 enzymaticly reacts G a 01 by enzymatic study (View interaction)
Pak3 physically interacts with CDC42 by solid phase assay (View interaction)
TGM2 enzymaticly reacts G a q by enzymatic study (View interaction)
G a 1 binds to Rgs4 by pull down (View interaction)
CDC42 physically interacts with Pak3 by pull down (View interaction)
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Open access under CC BY license.1. Introduction cal roles for serotonylation have been reported, including a func-Posttranslational modiﬁcations including phosphorylation,
acetylation, methylation or glycosylation are essential in cellular
signaling cascades and used to regulate protein activity [1,2].
Another, but less understood posttranslational modiﬁcation is the
attachment of serotonin, a biogenic monoamine, to glutamine
residues [3,4]. Serotonin is transferred in a transglutaminase
(TGM)-dependent manner to G proteins in aggregating
mouse platelets [3]. Upon this discovery, several pathophysiologi-al Societies. Published by Elsevier
al modiﬁcation; TGM, trans-
, cysteamine
ms Biology Centre & Dept. of
ding, 80 Tennis Court Road,
inckel), mr559@cam.ac.uktion in diabetes and primary pulmonary hypertension, indicating
that this modiﬁcation plays an important biological role [5–12].
Interestingly, it has recently been shown that monoamine
transfer by TGM is not limited to serotonin; also norepinephrine
and dopamine were found to be TGM substrates in transamidation
reactions [13,14]. Although no biological roles for dopaminylation
and norepinephrinylation are yet known, these observations indi-
cate that transfer of biogenic monoamines (= monoaminylation)
could be representatives for a broad class of previously neglected
posttranslational modiﬁcations.
In the present study, we address the biological function of an-
other monoamine incorporation, histaminylation. Histamine (HA)
plays an important biological role as neurotransmitter and in the
inﬂammatory response [15]. In these cases, histamine signaling is
induced by G protein coupled receptors, that are activated through
binding histamine as non-covalent ligand [16,17]. How-
ever, although still lacking a recognized function, work in theB.V. Open access under CC BY license.
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into proteins [18–21].
Here we show that protein incorporation of histamine occurs in
mast cells, and is catalyzed by transglutaminase II (TGM2). We
identify glutamine residues in the catalytic core of the G proteins
Gaq, Gao1 and Cdc42 to be modiﬁed by histamine attachment,
and provide evidence that this modiﬁcation leads to their constitu-
tive activation. Hence, histamine transfer to glutamine residues is a
regulatory posttranslational modiﬁcation. Targeting G proteins
Gao, Gaq and Cdc42, this novel modiﬁcation is thus involved in
mammalian signaling.
2. Materials and methods
2.1. Protein expression
Expression of TGMs was determined by PCR using the primers
listed in Table 1. Constructs for the expression of N-terminally
tagged GST and 6His fusion proteins of Gao1 (NP_059023), Gaq
(NP_032165), Cdc42 (NP_001782), RGS4 (NP_058910 and Pak3BD
(NP_032804 [AA 70–106]) were produced according to standard
protocols. In brief, RNA frommouse tissue was isolated and reverse
transcribed. Fragments corresponding to the respective small and
heterotrimeric GTPases as well as effector protein domains were
ampliﬁed by PCR. The respective fragments were introduced into
the pGEM-T vector (Promega) and subcloned into the pGEX4T-1
(GE Healthcare) or pQE-40 (Qiagen). pGEX-p50RhoGAPD was a gift
from A. Hall (MSKCC, New York [22]). For the expression of GST-
WDTAGQERFR, a corresponding oligonucleotide was synthesized
and cloned into the EcoRI/NotI sites of pGEX4T-1along side a linker
(PASGGGAVNPASGGGGA). Recombinant fusion proteins were ex-
pressed and puriﬁed from E. coli BL21(DE3) competent cells with
pREP4-groESL [23,24]. 6His-Gao1 was produced by the autoin-
ductory expression procedure [25].
2.2. Monoaminylation assay
In vitro transamidation reactions were carried out as previously
described [26,27]. rmTGM1, gpTGM2 and rhTGM3 were obtained
commercially (Zedira), and 0.7 U rhTGM3 was activated with
0.2 lg Dispase II (Roche) and 50 mM Tris/HCl at pH 8.0 in a total
volume of 10 ll at 30 C for 20 min. For each protein, 200 pmol
were mixed with 1 mM DTT, 10 mM CaCl2, Complete Protease
Inhibitors without EDTA and the indicated concentrations of
[3H]-labeled HA (GE Healthcare) or monodansylcadaverine (MDC)
in 50 mM Tris/HCl, pH 8.0. Monoaminylation was initiated by theTable 1
Oligonucleotides for assessing of transglutaminase expression by RT-PCR.
Transcript Orientation Sequence
mTGM1 forward 50-GTTTGAATATGATGAGCTGATTGTG-30
reverse 50-TACTATGGAACAGAAGCACAGATTG-30
mTGM2 forward 50-GCCAACCACCTGAACAAACT-30
reverse 50-CTTGATTTCGGGATTCTCCA-30
mTGM3 forward 50-CTGGAGAAGATCTGAATTTCATTGT-30
reverse 50-AATGTCTTCTTCAAACTGTCCAAAG-30
mTGM4 forward 50-AGCAGAGTACATCCTTAATGACACC-30
reverse 50-CCAGGTAGATGTCTACTGTGAGGTT-30
mTGM5 forward 50-TTCTGGAGAATATGAAGAAGGACAC-30
reverse 50-TTTAGGAACACCTCTCTCTCTTGAA-30
mTGM6 forward 50-CAGCTCACAGTTCCCAGACA-30
reverse 50-GAGTTACCTGGGCTGAGCTG-30
mTGM7 forward 50-GGGAGTGGCCTCATCAATGG-30
reverse 50-CCTTGACCTCACTGCTGCTGA-30
GAPDH forward 50-ACCACAGTCCATGCCATCAC-30
reverse 50-TCCACCACCCTGTTGCTGTA-30addition of 250 mU rmTGM1, 5 mU gpTGM2, 25 mU rhTGM3 and
incubated for 30 min at 30 C to give a total volume of 25 ll. To
determine the extent of histaminylation, the reaction was termi-
nated with 1 mg/ml BSA and 25% (v/v) PCA. After 2 h on ice, the
precipitated protein was separated from unbound HA by ﬁltration
over GF-C ﬁlter disks and washed three times with ice cold wash-
ing buffer (100 mM PCA, 100 mM NaCl and 0.1% (v/v) Tween-20 in
PBS). The radioactivity was measured with 5 ml ReadyProtein+ in a
scintillation counter (Beckman). To determine incorporation of
MDC, samples were subjected to SDS–PAGE, observed under UV
light (BioRad GelDoc 2000) and stained using coomassie.
Culture of the mouse lymphoblast-like mastocytoma cell line
P815 was as detailed previously [28]. Histaminylation of 1  106
cell/well was determined as described [6], with TGM inhibition
performed by applying 0.5 mM CTA where indicated.
2.3. Determination of GTPase activity
TGM2-dependent GTP hydrolysis of 6His-Gao1 or 6His-
Cdc42 was tested after histaminylation as described above fol-
lowed by the addition of 5 mM MgCl2, 5 lM GTP and 0.1 lCi
[a-32P]-GTP or [g-32P]-GTP (GE Healthcare) in a total volume of
30 ll. For thin layer chromatography, the sample was incubated
at 37 C for 45 min, terminated with 1% (w/v) SDS and analyzed
on polyethyleneimine-cellulose plates with 1 M LiCl as the solvent
[29]. For ﬁlter experiments, the sample was incubated at RT for
15 min, ﬁltered over NC ﬁlter disks and washed three times with
ice cold dilution buffer (50 mM Tris pH7.6, 50 mM NaCl, 5 mM
MgCl2). The radioactivity was measured with 5 ml ReadyProtein+
in a scintillation counter (Beckman). GTPase effector binding activ-
ity was assayed using 6His-tagged Cdc42 or Gao1 and GST-
tagged Pak3 Cdc42 binding domain (Pak3BD) or RGS4, respectively.
For pull-down experiments, monoaminylation of 6 lM 6His-
Cdc42 or 2.5 lM 6His-Gao1 was conducted as described above
with 200 lM HA and gpTGM2. The proteins were then preloaded
with 500 lM GTP, GDP or GMP-PNP in the presence of 0.5 mM
EDTA and subjected to GTP hydrolysis by the addition of 5 mM
MgCl2 and in the case of Cdc42, 0.2 lM GST-p50RhoGAPD. After
15 min at 37 C, 40 nM GST-Pak3BD or 2 lMGST-RGS4 were added
together with 20 ll of Ni–NTA magnetic agarose beads (Qiagen) in
ice-cold interaction buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, 0.01% (v/v) Tween-20, 10% (v/v) glycerol) and inverted
for at least 4 h at 4 C. Unbound proteins were then removed by
extensive washing. Effector binding was determined by immuno-
blotting and densitometry.
For experiments involving immobilized effectors, 10 lg/ml
GST-Pak3BD was incubated on a MaxiSorp surface (Nunc) over-
night. After extensive washing with water and blocking (5% milk
powder in PBST, 30 min), 0.35 lM monoaminylated and nucleo-
tide-preloaded 6His-Cdc42 was added to the surface together
with 0.2 lMGST-p50RhoGAPD in interaction buffer, and incubated
for 30 min at 30 C. While extensive washing and blocking steps
were applied, GTPase binding was determined by immunodetec-
tion using 5His-speciﬁc antibodies (Qiagen) and TMB (Thermo
Scientiﬁc) by a colorimetric quantiﬁcation.
2.4. Identiﬁcation of monoaminylated peptides by selective reaction
monitoring and LIT fragmentation
Puriﬁed GST-fusion proteins of Gao1 and Gaq were incubated
with or without TGM2 in the presence of HA. After blocking
the reaction, proteins were reduced with dithiothreitol and tris-
(2-carboxyethyl)-phosphine, alkylated with iodoacetamide, and
digested with trypsin as previously described [30]. The digests
were ﬁltered with Amicon-Ultra 3k centrifugal ﬁlters (Millipore),
vacuum dried and re-suspended in a water/acetonitrile/formic acid
Fig. 1. TGM2-dependent protein incorporation of histamine. (a) Histamine added extracellularly is protein-incorporated. P815 mastocytoma (1  106) cells were treated with
1 lCi [3H]-histamine ([3H]-HA), with and without the transglutaminase (TGM) inhibitor cysteamine (CTA), proteins precipitated with PCA, and analyzed by scintillation
counting. The [3H]-HA-treatment resulted in radioactive labeling of the protein fraction; transfer of the label was inhibited by CTA. (b) TGM paralogues are expressed in
mastocytoma cells. RT-PCR experiments addressing TGM paralogues 1–7 from P815 cDNA. (c) TGM2 transfers histamine to G proteins. 8 lM GST, GST-Cdc42, GST-Gao1, GST-
Gaq or dimethyl caseine (DMC) were incubated for 30 min with 0.3 lM [3H]-HA in combination with TGM1, TGM2 or TGM3. Proteins were precipitated, ﬁltered and analyzed
by scintillation counting. (d) Stoichiometry of Gao1 histaminylation. 1.6 lM GST-Gao1 and 5 mU TGM2 were incubated for 60 min with differing amounts of [3H]-HA and
assayed for radioactivity.
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water to acetonitrile gradient at a ﬂow rate of 300 nl/min on a Zor-
bax 300SB-C18 nanocolumn (Agilent) using a 2D Ultra nano HPLC
(Eksigent). Structure-speciﬁc information was obtained on a
QTRAP5500 (AB/Sciex) hybrid triple quadrupole/ion trap mass
spectrometer that was equipped with a Nanospray III ion source
(AB/Sciex) and coupled online to the nanoLC system. SRM (Q1/
Q3) transitions corresponding to tryptic peptides containing the
catalytic glutamine of Gao1 and Gaq were calculated with MRM
pilot 2.0 (Applied Biosystems) and Chemdraw (Cambridgesoft)
and tested on unmodiﬁed (non-TGM exposed) digests to tune the
instrument parameters. Afterwards, Q1/Q3 masses were adjusted
for the expected mass shift in case of a histaminylation (Fig
2a,b). Fragment ion (MS/MS) spectra of the histaminylated and
unmodiﬁed Gao1 peptide were obtained on the QTRAP instrument
(ion trap) operating in enhanced product ion (EPI) mode and tar-
geting a precursor m/z of 493.3 for the histaminylated Gao1 pep-
tide and 446.2 for the unmodiﬁed doubly-charged Gao1 peptide.
2.5. Statistical analyses
All data are presented as the means ± standard deviation, and p
values are from two-tailed Student’s t tests. Values of p < 0.05 were
considered as statistically signiﬁcant.
3. Results
3.1. Histamine is incorporated into the mastocytoma proteome in a
TGM- dependent manner
We found radioactivity in protein fractions obtained from amas-
tocytoma cell line (P815) that had been treatedwith tritium-labeledhistamine ([3H]-HA) (Fig 1a). This indicates that HA added extracel-
lularly is incorporated into the proteome, conﬁrming previous re-
ports [18–21]. Since it has been reported that histamine is a
substrate for transglutaminases (TGM, E.C. 2.3.2.13, [20]) we specu-
lated that member(s) of this enzyme class could catalyze the HA
transfer. Indeed, treating P815 cells with the TGM inhibitor cyste-
amine (CTA) strongly reduced radiolabeling of the P815 protein ex-
tract (Fig 1a), providing evidence that transglutaminases could
catalyze protein histaminylation, which would result in the forma-
tion of x(c-glutamyl)histaminyl residues.
Next, we performed RT-PCR experiments to establish whether
transglutaminases are expressed in P815 cells. Expression of trans-
glutaminase isozymes TGM2 and TGM3 was conﬁrmed, whereas
no PCR product was obtained for isozymes TGM 1, 4, 5, 6, and 7
(Fig 1b). Known targets of these TGMs are GTPases of the Rho
and Rab family, such as Cdc42, and the heterotrimeric GTPases
Gaq and Gao1 [3,5–7,31,32] These proteins puriﬁed as GST fusion
were incubated with either TGM1, TGM2 or TGM3 in the presence
of [3H]-HA. No labeling was detected when TGM1 nor TGM3 were
incubated with the substrates. However, TGM2 incubation resulted
in radiolabeling of the G proteins and the positive control dimethyl
caseine (DMC), but not GST alone (Fig 1c). Thus, TGM2 catalyzed a
transfer of HA to the G proteins Gao1, Gaq and Cdc42.
3.2. TGM2 transfers histamine to a single glutamine residue located
within the catalytic core of Gao1 and Gaq
To determine the stoichiometry of the histaminylation, we
incubated GST-Gao1 and TGM2 for 60 min with different [3H]-
HA concentrations. After correction for unspeciﬁc binding, the
HA/GST-Gao1 ratio approached the saturation closely to 1, indicat-
ing histaminylation of a single residue (Fig 1d). We next used
Fig. 2. TGM2-dependent histaminylation of catalytic glutamines. (a) SRM assays identify the Gao1 catalytic-core glutamine as recipient of histaminylation. GST-Gao1 was
incubated with 200 lM HA in the presence (upper panel) or absence (lower panel) of TGM2, digested with trypsin and analyzed by LC–MS/MS. Analyzed SRM (Q1/Q3)
transitions (in m/z) are given in the legend. Please not that the corresponding Cdc42 peptide could not be analyzed as it exceeded the mass range (50–1200 Da m/z) of the
mass spectrometer [39]. (b) Similar to (c), but analyzing Gaq. (c) MS/MS spectra of the histaminylated Gao1 precursor peptide LFDVGGQHAR and (d) of the unmodiﬁed Gao1
precursor peptide LFDVGGQR. (e) Posttranslational histaminylation of glutamine residues. Transamidation of HA to a protein-bound glutamine residue, resulting in the
formation of a x(c-glutamyl)histaminyl residue and release of ammonia. (f) Schematic illustration of the catalytic-core Gao1 peptide containing a sole glutamine residue,
modiﬁed with histamine. (g) A linear GTPase core peptide confers TGM2 reactivity. The Rab core peptide WDTAGQERFR, conserved in several GTPases, was fused with GST. Then
GST or GST-WDTAGQERFR were incubated with TGM2 and the ﬂuorescent TGM substrate MDC. Transamidation were determined using SDS–PAGE and UV detection.
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for localizing the modiﬁcation. Using a nano LC- (nanoLC 2D Ultra,
Eksigent) coupled hybrid triple quadrupole/ion trap mass spec-
trometer (QTRAP5500, AB/Sciex), we established selective reaction
monitoring (SRM) assays [30,33] for tryptic digests of the G pro-
teins Gao1, Cdc42 and Gaq, taking into account a mass shift
(+94) caused by potential histaminylations (Fig 2e). Peptides corre-
sponding to the histaminylated catalytic center of Gao1 (aa 199–
206, Fig 2a) and Gaq (aa 203–210, Fig 2b) were detected by three
SRM transitions each (upper panels). These SRM signals were spe-
ciﬁc to the enzymatic modiﬁcation of Gao1 or Gaq, as they were
not detected in case HA and G proteins were incubated in the ab-
sence of TGM2 (lower panels).
The catalytic core tryptic peptide of Gao1 peptide contains a sin-
gle glutamine only (Fig 2f). Therefore,we also recordedMS/MS spec-
traof theTGM2modiﬁed (Fig2c) andnon-modiﬁed (Fig2d)peptides
using the linear ion trap (LIT) mode of the Qtrap instrument. When
compared to the MS/MS spectra of the corresponding unmodiﬁed
peptide (Fig 2d), y-fragment ions of the modiﬁed peptide (Fig 2c)exhibited am/z shift of +94, providing further indication for a hista-
minylation. Thus, both SRM assays and ion trap fragmentation indi-
cate that TGM2 catalyzes the transfer of HA to the catalytic core
peptide of G proteins Gao1 (Q205) and Gaq (Q209).
Finally, we tested for sequence-speciﬁcity of TGM2-dependent
histaminylation using a linear peptide (WDTAGQERFR) represent-
ing a common and highly conserved, G protein catalytic core. We
generated a fusion protein of GST, a linker, and this peptide. When
incubated with TGM2 and the ﬂuorescent monoamine analogue
MDC, the fusion protein was labeled, whereas GST alone (contain-
ing 6 glutamine residues), was not labeled (Fig 2f). Hence, monoa-
minylation of a synthetic G protein core peptide suggests that the
speciﬁcity of TGM2 appears to be determined by a speciﬁc feature
of the G protein catalytic core sequence.
3.3. Glutaminyl-histaminylation activates G proteins Gao1 and Cdc42
To test for biological function of the histaminylation, we tested
whether this modiﬁcation inﬂuences the activity of the G proteins.
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sion of [a-32P]-GTP to [a-32P]-GDP in the presence of unmodiﬁed
and histaminylated Gao1. Whereas most GTP was hydrolyzed in
the presence of naïve Gao1, intensive GTP autoradiography was
preserved in its histaminylated form (Fig 3a). Thus, histaminylated
Gao1 exhibits reduced GTPase activity, indicating that it is kept in
its active (GTP-bound) conformation.
To verify an activation of Gao1 by histaminylation, we studied
the complex formation of Gao1 with its binding partner RGS4. This
protein is known to bind preferentially to active Gao proteins [34].
Gao1 was pre-loaded with GTP, GDP or GMP-PNP, a non-
hydrolysable GTP analog leading to constitutive G protein activa-
tion. Then, the protein was incubated with recombinant RGS4,
and the resulting protein complex was immunoprecipitated.
Analyzed by western-blotting and densitometry, Gao1 strongly
bound RGS4 in the presence of GMP-PNP, whereas GDP- and
GTP-preloaded Gao1/RGS4-binding was signiﬁcantly weaker
(Fig 3b). Remarkably, histaminylated Gao1 formed the RGS4
complex to the same extent as GMP-PNP pre-loaded Gao1. Hence,
histaminylation stabilizes the Gao1/RGS4 complex, indicating that
Gao1 is constitutively activated by histaminylation.
We next analyzed the activity of the small GTPase Cdc42 as a
function of histaminylation. As determined by [c-32P]-GTP hydro-
lysis experiments, TGM2-catalyzed modiﬁcation of the G protein
leads to a strong decrease in catalytic activity compared to samples
incubated with HA alone (Fig. 3c).
It has previously been shown that the binding afﬁnity of Cdc42
and the Pak G protein binding domain increases upon activation of
the G protein [35,36]. To provide additional evidence if histaminy-
lation leads to activation of Cdc42, we thus studied the ability of
Cdc42 to form a complex with the G protein binding domain ofFig. 3. Histaminylated GTPases Cdc42 and Gao1 show increased effector binding and dec
layer chromatography followed by autoradiography of [a-32P]-GTP incubated with na
stabilizes a Gao1/RGS4 complex. 6His-Gao1, or TGM2/HA-exposed 6His-Gao1, was loa
was immunoprecipitated (n = 5) and analyzed densitometrically. ⁄p < 0.05. (c) Histaminy
TGM2/HA or HA alone, loaded with [c-32P]-GTP, and GTP hydrolysis was induced by add
using scintillation. (d, e) Histaminylation stabilizes a Cdc42/Pak3 complex. (c) 6His-Cdc4
with immobilized GST-Pak3BD in the presence of 0.2 lM p50RhoGAPD. Binding of 6His
HA. (n = 3) ⁄p < 0.05. (d) Pulldown of 40 nM GST-Pak3BD with 6 lM 6His-Cdc42 pre-trPak3 (Pak3BD) [37,38] using a multiwell-based binding assay
as described in the Materials and Methods section, and co-
precipitation. Histaminylation of Cdc42 signiﬁcantly increased its
binding to Pak3BD in the multiwell-based binding assay (Fig 3c).
This result was additionally conﬁrmed by pulldown experiments,
where a 6His-Cdc42/GST-Pak3BD complex was puriﬁed using a
Ni–NTA matrix and analyzed by western-blotting. When Cdc42
was histaminylated, or pre-loaded with the non-hydrolysable
GTP analogue GMP-PNP, a signiﬁcantly higher amount of Pak3BD
was co-precipitated with Cdc42 (Fig 3e). Thus, catalytic-core
histaminylation increases the GTP hydrolysis activity, and stabi-
lizes protein interactions associated with the active state of
Cdc42 and Gao1. Taken together, these experiments indicate that
the analyzed G proteins become constitutively active when
histaminylated.
4. Discussion
It has been reported in 1961 that histamine is incorporated into
proteins [17], and this discovery has been substantiated in the
1980s [21]. However, the function of protein-bound histamine
has not been clearly deﬁned until the present study. Here we pro-
vide evidence that histaminylation (histamine incorporation) func-
tions as regulatory posttranslational modiﬁcation. A selected group
of GTPases, either known targets of TGM (Cdc42), or involved in
regulation of vesicular HA transport (Gao1 and Gaq), were shown
to be histaminylated. These proteins become constitutively active
upon this modiﬁcation.
Wehaveshownthathistaminylation iscatalyzedbytransglutamin-
ase TGM2,modifying only speciﬁc glutamine residues. Eventually, this
transamidation leads to the formation of a x(c-glutamyl)histaminylreased GTP hydrolysis. (a) Histaminylation of G proteins prevents GTP hydrolysis. Thin
tive Gao1, histaminylated (TGM2 exposed) Gao1, and buffer. (b) Histaminylation
ded with GMP-PNP, GDP and GTP and incubated with 2 lM GST-RGS4. The complex
lation of the Rho GTPase Cdc42 prevents GTP hydrolysis. 6His-Cdc42 was exposed to
ition of MgCl2 and 0.2 lM p50RhoGAPD. After ﬁltration, [c-32P]-GTP was quantiﬁed
2 was pre-loaded with GMP-PNP, GDP and GTP, and incubated in multiwell plates
-Cdc42 was strongly enhanced when the protein was pre-incubated with TGM2 and
eated with GMP-PNP, GDP, GTP and GTP + TGM2/HA.
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Cdc42 (modiﬁcation at glutamine Q61), Gao1 (Q205) and Gaq (Q209)
(Fig 2e). (i) thin layer chromatography, (ii) quantiﬁcation of their
GTPase activity and (iii) increased binding to their effector domains
indicated that these G proteins become constitutively active upon his-
taminylation. As the activity of the mast cell’s vesicular monoamine
transporter (VMAT2), implicated in histamine uptake, depends on
Gaq andGao [31], these ﬁndings imply that histaminylation functions
in its auto-regulation. High cytosolic and/or vesicular HA concentra-
tions could thus induce histaminylation of these GTPases, modulating
the transporter’s activity and ﬁne-tuning vesicular HA content.
However, these investigations do not allow concluding on the
presence or absence of other targets for histaminylation. Follow
up genome scale studies have now to clarify how broad the cellular
function of this novel posttranslational modiﬁcation is in total, and
how many other proteins are functionally regulated by histaminy-
lation. In this context, also other monoaminylations involving sero-
tonin [3], and recently dopamine and norepinephrine [13,14], have
been shown to be transferred to glutamine residues in a TGM-
dependent manner. Histaminylation is thus a member of a larger
family of previously neglected posttranslational protein modiﬁca-
tions (monoaminylations) that are implicated in mammalian sig-
naling, whose spectra of biological function needs now to be
deﬁned [40].
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